A Multinational, Multicenter, Masked, Randomized, Controlled Study to Assess the Safety and Efficacy of Lucinactant for Inhalation Versus nCPAP Alone in Preterm Neonates 26 to 32 Weeks Gestational Age With RDS

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 26 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sinapultide (Primary)
Indications Neonatal respiratory distress syndrome; Respiratory insufficiency
Focus Therapeutic Use
Sponsors Windtree Therapeutics

Most Recent Events

27 Apr 2023 Status changed from suspended to discontinued.
11 Jan 2021 Status changed from recruiting to suspended by reason of corporate business reasons.
11 Sep 2020 Planned number of patients changed from 90 to 130.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight